JAIME KWEON: Open Payments
NPI 1417480229 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 62 payments from 12 companies in 2025. Trend: 2023 $739 · 2024 $894 · 2025 $1,514
Food & beverage: $1,514
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $553 |
| Abbott Laboratories | 8 | $264 |
| Dexcom, Inc. | 12 | $262 |
| BETA BIONICS, INC. | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Lilly USA, LLC | 3 | $60 |
| CeQur Corporation | 1 | $57 |
| Insulet Corporation | 2 | $48 |
| Tandem Diabetes Care, Inc. | 3 | $47 |
| Amgen Inc. | 1 | $23 |
Products named: Ozempic, FREESTYLE LIBRE 3, DEXCOM G7 GSS (161), Dexcom G6 Transmitter, iLet Bionic Pancreas, CeQur Simplicity, GVOKE HYPOPEN, Omnipod.
Industry payments across CT — which companies pay providers there.
